NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA

Fidanacogene elaparvovec for treating moderately severe or severe haemophilia B [ID4032]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
Yes, stakeholders identified the following potential equality issues and requested that NICE: • Considers that moderate and severe haemophilia B is rare in women and that the clinical trial did not include women. But there are 6 women in the UK with moderate haemophilia B and at least 1 with severe haemophilia B who potentially meet the criteria for access to this treatment. NICE should ensure that recommendations do not discriminate against them. • Ensures recommendations do not discriminate against people with HIV or historical hepatitis B or C

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
The remit is to appraise the clinical and cost effectiveness of fidanacogene elaparvovec within its anticipated marketing authorisation for treating moderately severe to severe haemophilia B. The anticipated marketing authorisation does not exclude any groups of people based on their sex, gender, or presence of chronic conditions (such as HIV, hepatitis B or C). The committee needs to be aware of these potential equality issues, but no further action should be needed.

3. Has any change to the draft scope been agreed to highlight potential equality

	issues?
	No.

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
	No.

Approved by Associate Director (name): … Linda Landells

Date: 18 October 2023